The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein
IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med.1994;330:956-961.
The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during
coronary intervention in refractory unstable angina: the CAPTURE study. Lancet.1997;349:1429-1435.
The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin
during percutaneous coronary revascularization. N Engl J Med.1997;336:1689-1696.
The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial
to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa
The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications
of percutaneous coronary intervention: IMPACT-II. Lancet.1997;349:1422-1428.
The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on
adverse cardiac events in patients with unstable angina or acute myocardial
infarction undergoing coronary angioplasty. Circulation.1997;96:1445-1453.
Ronner E, Dykun Y, Van den Brand MJBM.
et al. Platelet glycoprotein IIb/IIIa receptor antagonists: an asset for treatment
of unstable coronary syndromes and coronary intervention. Eur Heart J.1998;19:1608-1616.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients
with acute coronary syndromes. N Engl J Med.1998;339:436-443.
Tung CY, Granger CB, Sloan MA.
et al. for the GUSTO-I Investigators. Effects of stroke on medical resource use and costs in acute myocardial
Dorros G, Cowley MJ, Simpson J.
et al. Percutaneous transluminal coronary angioplasty: report of complications
from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation.1983;67:723-730.
Serruys PW, De Jaegere P, Kiemeneij F.
et al. for the BENESTENT Study Group. A comparison of balloon-expandable-stent implantation with balloon
angioplasty in patients with coronary artery disease. N Engl J Med.1994;331:489-495.
Fischman DL, Leon MB, Baim DS.
et al. for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty
in the treatment of coronary artery disease. N Engl J Med.1994;331:496-501.
Schomig A, Neumann F-J, Kastrati A.
et al. A randomized comparison of antiplatelet and anticoagulant therapy after
the placement of coronary-artery stents. N Engl J Med.1996;334:1084-1089.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients
with multivessel disease. N Engl J Med.1996;335:217-225.
Zijlstra F, de Boer MJ, Hoorntje JCA.
et al. A comparison of immediate coronary angioplasty with intravenous streptokinase
in acute myocardial infarction. N Engl J Med.1993;328:680-684.
Grines CL, Browne KF, Marco J.
et al. A comparison of immediate angioplasty with thrombolytic therapy for
acute myocardial infarction. N Engl J Med.1993;328:673-679.
The GUSTO-IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue
plasminogen activator for acute myocardial infarction. N Engl J Med.1997;336:1621-1628.
Weaver WD, Simes RJ, Betriu A.
et al. Comparison of primary coronary angioplasty and intravenous thrombolytic
therapy for acute myocardial infarction: a quantitative review. JAMA.1997;278:2093-2098. [published correction appears in JAMA. 1998;279:1876].
Tiefenbrunn AJ, Chandra NC, French WJ.
et al. Clinical experience with primary percutaneous transluminal coronary
angioplasty compared with alteplase in patients with acute myocardial infarction:
a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol.1998;31:1240-1245.
Mahaffey KW, Harrington RA, Simoons ML.
et al. Stroke in patients with acute coronary syndromes: incidence and outcomes
in the PURSUIT trial. Circulation.1999;99:2371-2377.
Gore JM, Granger CB, Simoons ML.
et al. Stroke after thrombolysis: mortality and functional outcomes in the
GUSTO-I trial. Circulation.1995;92:2811-2818.
Longstreth Jr WT, Litwin PE, Weaver WD.and the MITI Project Group. Myocardial infarction, thrombolytic therapy, and stroke: a community-based
De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence
and clinical predictive factors. J Am Coll Cardiol.1992;19:289-294.
Simoons ML, Maggioni AP, Knatterud G.
et al. Individual risk assessment for intracranial haemorrhage during thrombolytic
Mahaffey KW, Granger CB, Sloan MA.
et al. Risk factors for in-hospital nonhemorrhagic stroke in patients with
acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation.1998;97:757-764.
Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis
and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation.1994;90:1624-1630.
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)
IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin
for acute coronary syndromes. Circulation.1994;90:1631-1637.
Granger CB, Hirsch J, Califf RM.
et al. Activated partial thromboplastin time and outcome after thrombolytic
therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation.1996;93:870-878.